Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-006 MK-2140 in aggressive and indolent B-cell malignancies
CTR20222465Phase 2Active
- Sponsor
- MSD
- Start
- Dec 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of zilovertamab vedotin in B-cell malignancy, mantle cell lymphoma (MCL), Richter's syndrome (RS), follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by MSD. Started Dec 2022; status: active.
02
Drugs
zilovertamab vedotin
03
Conditions
B-cell malignancymantle cell lymphoma (MCL)Richter's syndrome (RS)follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20222465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222465.